Fjarde Ap Fonden Amgen Inc Transaction History

Fjarde Ap Fonden

$9.8 Billion
Q3 2024

A detailed history of Fjarde Ap Fonden transactions in Amgen Inc stock. As of the latest transaction made, Fjarde Ap Fonden holds 145,029 shares of AMGN stock, worth $38.2 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares

145,029

Previous 158,262 8.36%

Holding current value

$38.2 Million

Previous $45 Million 3.85%

% of portfolio

0.48%

Previous 0.5%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$309.38 - $337.38 $4.09 Million - $4.46 Million	-13,233 Reduced 8.36%	145,029 $46.7 Million
Q1 2024 Apr 25, 2024	BUY	$268.87 - $324.56 $1.29 Million - $1.55 Million	4,788 Added 3.12%	158,262 $45 Million
Q4 2023 Feb 14, 2024	BUY	$255.7 - $288.46 $791,135 - $892,495	3,094 Added 2.06%	153,474 $44.2 Million
Q3 2023 Oct 23, 2023	SELL	$218.65 - $271.46 $842,239 - $1.05 Million	-3,852 Reduced 2.5%	150,380 $40.4 Million
Q2 2023 Aug 02, 2023	SELL	$214.27 - $253.37 $385,686 - $456,066	-1,800 Reduced 1.15%	154,232 $34.2 Million
Q1 2023 May 15, 2023	BUY	$225.79 - $275.2 $327,395 - $399,040	1,450 Added 0.94%	156,032 $37.7 Million
Q4 2022 Feb 14, 2023	SELL	$229.03 - $291.01 $884,284 - $1.12 Million	-3,861 Reduced 2.44%	154,582 $40.6 Million
Q2 2022 Aug 11, 2022	BUY	$230.71 - $256.74 $2.7 Million - $3 Million	11,700 Added 7.97%	158,443 $38.5 Million
Q1 2022 May 13, 2022	SELL	$219.27 - $242.57 $2.44 Million - $2.7 Million	-11,116 Reduced 7.04%	146,743 $35.5 Million
Q4 2021 Feb 15, 2022	SELL	$198.88 - $227.6 $1.63 Million - $1.86 Million	-8,186 Reduced 4.93%	157,859 $35.5 Million
Q3 2021 Nov 15, 2021	SELL	$212.27 - $248.7 $551,902 - $646,620	-2,600 Reduced 1.54%	166,045 $35.3 Million
Q2 2021 Aug 12, 2021	SELL	$233.58 - $259.14 $2.78 Million - $3.08 Million	-11,900 Reduced 6.59%	168,645 $41.1 Million
Q1 2021 May 17, 2021	BUY	$221.91 - $258.6 $665,730 - $775,800	3,000 Added 1.69%	180,545 $44.9 Million
Q4 2020 Feb 12, 2021	SELL	$216.38 - $257.67 $1.17 Million - $1.39 Million	-5,400 Reduced 2.95%	177,545 $40.8 Million
Q3 2020 Nov 13, 2020	BUY	$234.65 - $260.95 $1.81 Million - $2.01 Million	7,700 Added 4.39%	182,945 $46.5 Million
Q2 2020 Aug 13, 2020	BUY	$197.81 - $242.74 $1.48 Million - $1.82 Million	7,500 Added 4.47%	175,245 $41.3 Million
Q1 2020 May 11, 2020	SELL	$182.24 - $241.7 $1.15 Million - $1.52 Million	-6,300 Reduced 3.62%	167,745 $34 Million
Q4 2019 Feb 10, 2020	BUY	$189.21 - $243.2 $737,919 - $948,480	3,900 Added 2.29%	174,045 $42 Million
Q3 2019 Oct 31, 2019	SELL	$174.11 - $208.62 $1.15 Million - $1.37 Million	-6,577 Reduced 3.72%	170,145 $32.9 Million
Q2 2019 Jul 17, 2019	SELL	$166.7 - $195.41 $1.52 Million - $1.78 Million	-9,100 Reduced 4.9%	176,722 $32.6 Million
Q1 2019 Apr 29, 2019	BUY	$180.87 - $203.88 $6.38 Million - $7.2 Million	35,298 Added 23.45%	185,822 $35.3 Million
Q4 2018 Jan 31, 2019	SELL	$178.4 - $208.25 $4.37 Million - $5.1 Million	-24,500 Reduced 14.0%	150,524 $29.3 Million
Q3 2018 Nov 09, 2018	SELL	$185.29 - $208.89 $2.28 Million - $2.57 Million	-12,281 Reduced 6.56%	175,024 $36.3 Million
Q2 2018 Jul 12, 2018	SELL	$166.05 - $186.51 $237,451 - $266,709	-1,430 Reduced 0.76%	187,305 $34.6 Million
Q1 2018 May 07, 2018	SELL	$169.43 - $198.0 $2.36 Million - $2.76 Million	-13,953 Reduced 6.88%	188,735 $32.2 Million
Q4 2017 Feb 12, 2018	BUY	$168.79 - $188.59 $5.07 Million - $5.67 Million	30,064 Added 17.42%	202,688 $35.2 Million
Q3 2017 Nov 07, 2017	BUY	$167.29 - $191.0 $440,139 - $502,521	2,631 Added 1.55%	172,624 $32.2 Million
Q2 2017 Aug 08, 2017	BUY	N/A	169,993	169,993 $29.3 Million

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

News

Stay updated on Fjarde Ap Fonden with notifications on news.

Account